Gilead announced an acquisition of Ouro Medicines in a deal valued at roughly $2.17 billion, acquiring OM336 (gamgertamig), a BCMA×CD3 bispecific T‑cell engager being tested in autoimmune hematologic diseases. The company said early phase data showed rapid B‑cell/plasma‑cell depletion and a differentiated safety profile; the FDA has granted Fast Track and Orphan Drug designations. Gilead also disclosed advanced talks to involve partner Galapagos in development and cost‑sharing, preserving worldwide commercialization rights outside China, where Keymed holds a license. The deal plugs a near‑term autoimmune franchise gap for Gilead and dovetails with its recent cell‑therapy M&A activity.